CDKN1C Antibody

What is CDKN1C and why is it important in research?

CDKN1C (cyclin-dependent kinase inhibitor 1C, also known as p57Kip2) is a cell cycle regulator and tumor suppressor gene belonging to the CIP/Kip family that includes p21Cip1/WAF1 and p27Kip1. It is crucial in research due to:

• Its role as a negative regulator of cell proliferation by inhibiting several G1 cyclin/CDK complexes

• Its maternally expressed, partially paternally imprinted status, making it important for genomic imprinting studies

• Its involvement in the Beckwith-Wiedemann syndrome and other growth disorders

• Its potential tumor suppressor function, with downregulation observed in various cancers

• Its critical function in embryonic development and tissue-specific roles in cell differentiation

The protein contains three main domains: an N-terminal CDK inhibitory domain, a central proline-alanine rich region (PAPA-repeats), and a C-terminal domain containing the PCNA binding site .

What applications are CDKN1C antibodies commonly used for?

CDKN1C antibodies have been validated for multiple applications in cellular and molecular biology research:

Researchers should select antibodies validated specifically for their intended applications and develop proper optimization protocols for each technique .

How should CDKN1C antibodies be stored and handled?

Proper storage and handling are critical for maintaining antibody functionality:

• Store at -20°C for long-term preservation (up to one year)

• For frequent use, store at 4°C for up to one month

• Avoid repeated freeze-thaw cycles as they can denature antibodies and reduce activity

• Most CDKN1C antibodies are supplied in PBS containing stabilizers such as 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• Some experimental protocols may require BSA-free formulations, which can be specially requested from manufacturers

• Always centrifuge briefly before use to bring all liquid to the bottom of the vial

• Follow lot-specific recommendations provided on Certificates of Analysis

What controls should be included when working with CDKN1C antibodies?

Proper controls are essential for interpreting results with CDKN1C antibodies:

Positive Controls:

• Cell lines with documented CDKN1C expression (e.g., 293T cells, mouse lung, rat kidney)

• Normal human placenta tissue (cytotrophoblasts and stromal cells show robust staining)

• Myoepithelial layer cells in normal breast tissue (show intense staining)

Negative Controls:

• Complete hydatidiform mole tissue (shows no nuclear labeling of cytotrophoblasts)

• CDKN1C-knockout or knockdown cells (using shRNA)

• Primary antibody omission control

• Isotype control antibody

Internal Controls:

• Intervillous trophoblastic islands (IVTIs) that demonstrate nuclear labeling can serve as internal controls in placental tissue studies

• Expression analysis in adjacent normal tissues when examining cancer samples

How can I optimize immunohistochemistry protocols for CDKN1C detection?

Optimizing IHC protocols for CDKN1C requires careful consideration of several factors:

• Antigen Retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is typically effective

• Antibody Concentration: Start with manufacturer's recommended dilution (typically 1:50-1:200) and optimize as needed

• Incubation Conditions:

  • Primary antibody: Overnight at 4°C or 1-2 hours at room temperature

  • Secondary antibody: 30-60 minutes at room temperature

• Detection System: HRP-conjugated secondary antibodies with DAB substrate provide good contrast

• Background Reduction:

  • Block with 5% normal serum from the same species as the secondary antibody

  • Include 0.1-0.3% Triton X-100 for improved penetration in tissue sections

• Counterstaining: Hematoxylin provides good nuclear contrast

Remember that CDKN1C shows differential localization (nuclear vs. cytoplasmic) depending on cell state, which is functionally significant .

How should researchers interpret different patterns of CDKN1C localization?

CDKN1C subcellular localization has significant functional implications that must be carefully interpreted:

• Nuclear Localization:

  • Associated with cell cycle arrest and differentiation

  • Often observed in post-mitotic, differentiating cells

  • Indicates active CDK inhibition function

  • Nuclear CDKN1C can repress E2F1-driven transcription

• Cytoplasmic Localization:

  • Observed in proliferating cells, particularly during early activation phases

  • In muscle satellite cells, cytoplasmic CDKN1C is detected in activated PAX7+/MYOD+ myoblasts

  • Suggests alternate functions beyond CDK inhibition

• Temporal Dynamics:

  • CDKN1C protein levels may oscillate during cell cycle progression in normal cells

  • IMAGe-mutant CDKN1C shows aberrant persistent expression

When interpreting localization data, researchers should:

• Document both intensity and subcellular distribution

• Correlate with proliferation markers (e.g., Ki67) and differentiation status

• Consider both nuclear and cytoplasmic functions in data interpretation

What explains the discrepancy between CDKN1C protein molecular weight in literature versus theoretical prediction?

Researchers often observe discrepancies between the theoretical molecular weight of CDKN1C (~32 kDa) and its apparent size on SDS-PAGE (~57 kDa):

These discrepancies can be explained by:

• Post-translational modifications: Phosphorylation, ubiquitination, and other modifications affect migration

• Protein structure: The proline-alanine rich region (PAPA repeats) causes abnormal migration in SDS-PAGE

• Isoforms: Alternative splicing produces different CDKN1C variants

• Technical factors: Running conditions, gel percentage, and buffer systems can affect apparent molecular weight

When validating a new antibody, researchers should:

• Run appropriate positive controls with known CDKN1C expression

• Compare results with published literature on the expected band pattern

• Consider using additional validation techniques such as immunoprecipitation followed by mass spectrometry

How can CDKN1C antibodies be used to study protein-protein interactions?

CDKN1C interacts with multiple proteins including CDKs, cyclins, E2F1, and others. To study these interactions:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate with anti-CDKN1C antibody and blot for interacting proteins

  • Alternatively, immunoprecipitate with antibodies against potential interactors (e.g., CDK7, CDK9, E2F1) and blot for CDKN1C

  • Use appropriate lysis buffers that preserve protein-protein interactions (e.g., TGN buffer with protease inhibitors)

• Proximity Ligation Assay (PLA):

  • Visualize protein-protein interactions in situ with <10nm proximity

  • Requires primary antibodies from different species against CDKN1C and its potential interactors

• Chromatin Immunoprecipitation (ChIP):

  • CDKN1C has been found to associate with E2F1-regulated promoters

  • Use ChIP with CDKN1C antibodies to identify DNA regions where CDKN1C is present

  • Sequential ChIP (ChIP-reChIP) can determine co-occupancy with other factors like E2F1

• GST Pull-down Assays:

  • Use bacterially expressed CDKN1C (with caution as it may form inclusion bodies)

  • Solubilize in 8M urea containing buffer before use in interaction studies

How can researchers investigate CDKN1C's role in transcriptional regulation?

CDKN1C has been shown to regulate transcription by inhibiting RNA polymerase II CTD phosphorylation through interaction with CDK7 and CDK9. To study this:

• RNA Polymerase II Phosphorylation Analysis:

  • Use antibodies specific for phosphorylated forms of RNA pol II CTD (Ser-2 and Ser-5)

  • Compare phosphorylation status in cells with normal, overexpressed, or knocked-down CDKN1C

• In Vitro Kinase Assays:

  • Immunoprecipitate CDK7 or CDK9 and assess their ability to phosphorylate GST-CTD fusion protein

  • Add purified CDKN1C to determine inhibition of kinase activity

  • Protocol example: Use kinase buffer (20 mM HEPES, pH 7.5, 50 mM NaCl, 10 mM MgCl₂, 1 mM DTT) with 5 mM ATP

• Chromatin Association:

  • Perform ChIP-seq with CDKN1C antibodies to identify genome-wide binding sites

  • Correlate with RNA pol II occupancy and phosphorylation status

  • Compare E2F1 binding sites with CDKN1C binding sites

• Transcriptome Analysis:

  • RNA-seq following CDKN1C modulation to identify affected gene networks

  • Focus on E2F1-target genes, as CDKN1C forms a negative feedback loop with E2F1

What methodologies are effective for studying mutations in CDKN1C?

Mutations in CDKN1C can lead to different phenotypes, including Beckwith-Wiedemann syndrome and IMAGe syndrome. To study these:

• Clonogenic Assays:

  • Transfect cells with wild-type, BWS-mutant, or IMAGe-mutant CDKN1C

  • Assess colony formation capacity after 7 days of culture

  • Quantify colonies with more than 50 cells

• Cell Cycle Analysis:

  • Synchronize cells using thymidine block (2 mM)

  • Transfect with wild-type or mutant CDKN1C constructs

  • Release from block and collect at various timepoints for flow cytometry

  • Analyze cell cycle distribution changes

• Protein Stability Assessment:

  • Perform cycloheximide chase experiments to track protein degradation rates

  • Western blot analysis shows that IMAGe-mutant CDKN1C maintains constant levels throughout the cell cycle, while wild-type and BWS-mutant levels oscillate

• Subcellular Localization Studies:

  • Use immunofluorescence to determine if mutations affect nuclear vs. cytoplasmic distribution

  • Create NLS-deficient CDKN1C constructs to specifically study cytoplasmic functions

How can researchers distinguish between cell-autonomous and non-cell-autonomous functions of CDKN1C?

Recent research has revealed that CDKN1C has both cell-autonomous and non-cell-autonomous functions:

• Mosaic Analysis with Double Markers (MADM) Technology:

  • Allows genetic manipulation at single-cell resolution in vivo

  • Can generate sparse genetic mosaics where individual mutant cells are uniquely labeled

  • Has revealed that CDKN1C has a growth-promoting cell-autonomous function in cortical development

• Conditional Knockout Approaches:

  • Generate floxed Cdkn1c alleles for tissue-specific deletion

  • Use site-specific recombination systems (Cre/loxP) with tissue-specific promoters

  • Requires consideration of CDKN1c's imprinted status (maternal expression)

  • Example: Intercrossing Flox(m)/+ Cdkn1c mice with Flox Pax7 line for muscle stem cell studies

• Retroviral Transduction in Single Fiber Cultures:

  • Allows manipulation of CDKN1C in specific cell populations

  • Can use CFP or other markers to track transduced cells

  • Useful for studying effects on satellite cell activation and muscle regeneration

• Transplantation Experiments:

  • Transplant CDKN1C-modified cells into wild-type hosts and vice versa

  • Assess behavior of donor cells in different host environments

  • Determine if phenotypes are caused by cell-intrinsic or systemic factors

What are the considerations for using CDKN1C antibodies in cancer research?

CDKN1C is considered a candidate tumor suppressor gene with complex expression patterns in cancer:

• Sample Preparation Considerations:

  • Laser microdissection is recommended to isolate specific cell populations

  • Distinguish between different cell types within tissues (e.g., luminal vs. myoepithelial cells in breast tissue)

• Expression Analysis Approaches:

  • Combine techniques: mRNA quantification (qPCR), protein detection (IHC), and genetic analysis (AI/LOH)

  • In breast cancer studies, CDKN1C mRNA levels were found to be reduced in 90% of cancers despite genetic alterations in only 19%

• Cell Type-Specific Analysis:

  • In normal breast tissue, intense CDKN1C staining is predominantly found in myoepithelial cells

  • In breast cancer, loss of CDKN1C expression from myoepithelial layer cells is common

  • Scoring system should account for both staining intensity and percentage of positive cells in each compartment

• Correlation with Clinical Parameters:

  • Evaluate CDKN1C expression in relation to tumor grade, histology, and molecular subtypes

  • Consider correlations with hormone receptor status (ER, PR) and HER2 expression